Long COVID
Conditions
Keywords
Long Covid, Post-COVID syndrome (PCS)
Brief summary
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.
Interventions
DRUGMaraviroc (MVC)
Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet
Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg
DRUGPlacebo, Maraviroc
Placebo of Maraviroc, 300mg
DRUGPlacebo, Atorvastatin
Placebo of Atorvastin, 10mg
Sponsors
HealthBio, Inc.
Lindus Health, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
l 1. ≥ 18 and ≤ 65 years of age at the time of consent 2. Meets WHO-defined post-COVID-19 condition (WHO definition: 'Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time). 3. One or more new onset symptoms that persisted for greater than 6 months after the diagnosis of acute COVID-19 infection. These symptoms include: cognitive impairment (brain fog), migraines, post-exertional malaise (PEM), myalgias, arthralgias, severe fatigue, tachyarrhythmias, postural orthostatic tachycardia syndrome (POTS), and shortness of breath. The previous COVID-19 infection should be documented in the form of a positive PCR laboratory test and/or medical records from a healthcare provider. The Long-COVID diagnosis should be documented in the medical records by a healthcare provider. 4. Negative Lyme screen, as measured by the AcuDart test. 5. Epstein-Barr Virus (EBV) DNA negative (centrally assessed). 6. A long hauler index (LHI) of \>0.71 7. A PROMIS Fatigue 10a T-score score \> 55 8. Participants of childbearing potential should be surgically sterilized or post-menopausal or must agree to take effective contraceptive measures during the study period. Adequate methods of birth control include: condoms, male or female, with or without a spermicide; diaphragm or cervical cap with spermicide; intrauterine device; any of the methods that require a prescription (such as contraceptive pills or path) or a male partner who has previously undergone vasectomy. 9. Participant is willing and able to participate in the study and comply with all study requirements. 10. Participant provided signed and dated IRB approved informed consent prior to initiation of any study procedures. 11. Participant is able to read and understand English.
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: 1. Participation in another therapeutic clinical trial in the past 2 months. 2. History of allergy or anaphylaxis or allergic reaction to any component of atorvastatin and/or maraviroc. 3. Uncontrolled hypothyroidism as defined as thyroid-stimulating hormone (TSH) and/or free thyroxine (FT4) values outside the local laboratory reference range at screening, or a change in thyroid hormone replacement dose within 6 weeks prior to screening. 4. Pre-COVID history of autoimmune conditions, migraines, neuropathy, inflammatory bowel disease (IBD), obsessive-compulsive disorder (OCD), or fatigue duration for ≥5 years, EBV infection, Lyme disease, fibromyalgia, arthritis, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD G3a or greater), chronic heart failure (CHF), arrhythmias, bleeding disorders, and anticoagulation therapy. 5. Presence of other conditions or differential diagnosis that better explains the symptoms of the patient than the suspected long COVID, in the opinion of the investigator. 6. Hepatic impairment, defined as Child-Pugh Score 7-9 (Class B) or greater. 7. Active/acute infectious diseases like tuberculosis, human immunodeficiency virus infection (HIV), cytomegalovirus (CMV), (vector based) Lyme, EBV, hepatitis B virus (HBV), hepatitis C virus (HCV). 8. Ongoing immunosuppressive therapy, such as cyclosporine A (CsA). 9. Use of statins within 6 months of randomization. 10. Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir, or lipid-modifying doses (\>1 gram/day) of niacin. 11. AST:ALT ratio\>1.5 12. Elevations in IL-8 (\>21 (pg/ml) and or IL-13 (\>6.1 pg/ml) (centrally assessed with IncellKINE panel). 13. Pregnant or breastfeeding 14. History of substance use disorder (including alcohol use disorder or cannabis use disorder per DSM-5 criteria) within 3 months of enrollment, OR current hazardous alcohol use as defined by: * Self-reported consumption \>14 drinks/week (males) or \>7 drinks/week (females), OR * Binge drinking (≥5 drinks on one occasion for males, ≥4 for females) ≥1 time per week, OR * Clinical judgment that alcohol use would interfere with study compliance or safety 15. Subjects with risk factors for myocardial ischemia/infarction, including but not limited to those with a prior history of MI, stroke, unstable angina, 16. Any significant disease or disorder, which, in the opinion of the Investigator, may either put the participants at risk 17. Azole antifungals (ketoconazole or itraconazole are not allowed) or macrolide antibiotics (clarithromycin is not allowed) 18. History of use of maraviroc and/or atorvastatin for the off-label treatment of Long COVID. Prohibited concomitant medications 19. Any statins within 6 months of randomization and between randomization and the participant's scheduled final visit 20. Other systemically administered drugs with significant immunosuppressive activity, such as azathioprine, tacrolimus, cyclosporine, methotrexate, or cytotoxic chemotherapy between randomization and the participant's scheduled final visit 21. Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including: 1. clarithromycin 2. cobicistat 3. elvitegravir/ritonavir 4. itraconazole 5. ketoconazole 6. nefazodone 7. protease inhibitors (except tipranavir/ritonavir) 8. telithromycin 22. Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis: 1. cyclosporine or gemfibrozil 2. tipranavir plus ritonavir or glecaprevir plus pibrentasvir 3. niacin (≥1 gram/day niacin)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fatigue | PROMIS Fatigue scores will be taken during screening (0-28 days before the first baseline) and at the EOT visit, week 12. | Fatigue will be measured via PROMIS Fatigue v1.0. The PROMIS Fatigue 10a assesses fatigue severity in the previous week. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The instrument translates the total raw score into a T-score with a mean of 50 and a standard deviation of 10. A score of 50 is the average for the United States general population (SD=10). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in dysautonomia symptoms as reflected by the Composite Autonomic Symptom Score (COMPASS-31) | Scores will be determined at Visit 1 (Day 1) and EOT (week -12) | To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on dysautonomia symptoms 12 weeks after treatment initiation in individuals with Long COVID. |
| Improved Cognitive Function, measured by the PROMIS (Patient-Reported Outcomes Measurement Information System) Cognitive Function v.2.0 - Short Form 6a | Difference in T-score measured at Visit 1 (Day 1) and EOT (week-12) | The PROMIS (Patient-Reported Outcomes Measurement Information System) Cognitive Function v.2.0 - Short Form 6a is a 6-item sub-set scale of the PROMIS Cognitive Function item bank that assesses patient-perceived cognitive deficits. Each item has five response options ranging in value from one to five. The total raw score for a short form with all questions answered, is the sum of the values of the response to each question and ranges between 6 and 30. The raw score is translated in a T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10. |
| To assess if maraviroc and atorvastatin decrease the Long Hauler Index (LHI) from baseline to week 12. | LHI will be measured at Screening and EOT (week-12) | To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on the LHI 12 weeks after treatment initiation in individuals with Long COVID. |
| To assess the proportion of participants with a PROMIS Fatigue T-score improvement from baseline ≥5 points 12 weeks after treatment initiation. | From baseline Visit 1 (Day-1) and EOT (week-12) | In subjects with Long COVID complying with the key protocol criteria (evaluable participants) who received 12 weeks of study treatment: ● Change in the proportion of subjects who improve their PROMIS T-score from baseline to week 12 in maraviroc/atorvastatin and placebo groups. |
| To determine the safety profile of maraviroc and atorvastatin in patients treated for Long COVID-19 | Adverse event collection will be done during every Visit (Day-1, Week-4, Week-8, Week-12, Week-16 (EOT) and EOS (28-42 Days after last dose) | Participants report data will be compiled as follows: Percentage of participants reporting AEs from Dose 1 to 28 days after the last dose. Percentage of participants reporting SAEs from Dose 1 to 28 days after the last dose. Percentage of participants reporting AEs leading to discontinuation. Percentage of participants reporting SAEs leading to discontinuation. |
| To evaluate IncellKINE Biomarkers | Screening and EOT (week-12) | To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on IncellKINE biomarker levels in individuals with Long COVID 12 weeks after treatment initiation. |
Countries
United States
Contacts
CONTACTBrad Fox
CONTACTBrian Brothen
Outcome results
None listed